Celularity Inc cash flow statement
In fiscal 2025, Celularity Inc's operations generated −$13.3m of cash; it spent $0 on capital projects, leaving free cash flow of −$13.3m.
Cash flow statement
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operations | −63 | −110 | −138 | −39 | −6 | −13 | −9 |
| Depreciation and amortisation | 8 | 9 | 9 | 9 | 8 | 7 | 6 |
| Stock-based pay | 4 | 40 | 16 | 0 | 12 | 11 | 12 |
| Capital spending | 28 | 6 | 5 | 1 | 0 | 0 | 0 |
| Free cash flow | −91 | −116 | −143 | −40 | −7 | −13 | −9 |
| Free cash flow after stock pay | −95 | −156 | −159 | −40 | −18 | −24 | −21 |
| Share buybacks | 0 | — | — | — | — | — | — |
| Shares issued | — | — | — | — | — | 1 | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −0 | 2 | −3 | −1 | −4 | −5 | 1 | −1 |
| Depreciation and amortisation | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 1 |
| Stock-based pay | 3 | 3 | 3 | 0 | 0 | 10 | 1 | 1 |
| Capital spending | 0 | 0 | — | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −0 | 2 | — | −1 | −4 | −5 | 1 | −1 |
| Free cash flow after stock pay | −3 | −1 | — | −1 | −5 | −15 | 0 | −2 |
| Shares issued | — | — | 2 | 0 | −1 | 0 | — | — |
Compare with peers
- Cytomx Therapeutics, Inc. cash flow
- Scynexis Inc cash flow
- Proqr Therapeutics N.V. cash flow
- Keros Therapeutics, Inc. cash flow
- Janux Therapeutics, Inc. cash flow
Head to head: CELU vs CTMXCELU vs SCYXCELU vs PRQR
More: Biotechnology stocks compared, Health Care sector, rankings of US companies